Chemicals & Small Molecules

MSU38225, an Nrf-2 inhibitor, elevates reactive oxygen species (ROS) levels and suppresses the proliferation of human lung cancer cells. Moreover, it augments the chemotherapy responsiveness of these cells in both in vitro and in vivo settings, making it a valuable agent in cancer research [1].

LM-41, a Flufenamic acid-derived TEAD inhibitor, significantly reduces the expression of CTGF, Cyr61, Axl, and NF2, and inhibits the migration of human MDA-MB-231 breast cancer cells [1].

AF-2112, a TEAD inhibitor derived from Flufenamic acid, significantly diminishes the expression of CTGF, Cyr61, Axl, and NF2.

Z-Gly-Pro-Arg-AMC hydrochloride is a fluorescent substrate used to assay the enzymatic activities of both trypsin and cathepsin K [1] [2].

Tripeptide-32 is a bioactive peptide recognized for its anti-aging properties, commonly utilized as an ingredient in cosmetics [1].

Duvakitug (SAR-447189) is a humanized IgG1-λ2 monoclonal antibody targeting TNFSF15/TL1A, which can be used to study ulcerative colitis and Crohn's disease.

Tulisokibart (PRA023) is a humanized IgG1-κ monoclonal antibody targeting TNFSF15/TL1A, with potential applications in researching inflammatory and fibrotic diseases, including Crohn's Disease (CD) [1] [2].

Tegoprubart is a monoclonal antibody targeting CD40 ligand (CD40L), which plays a critical role in costimulation. By inhibiting CD40L, it diminishes both cellular and antibody-mediated immune responses, fostering a more tolerant immune milieu. The efficacy of Tegoprubart has been confirmed in vivo within transplantation animal models.

PTBP1-RNA-binding inhibitor P6 TFA (PTBP1 α3-helix derived peptide P6 TFA) is a specific stapled peptide inhibitor of the splicing factor PTBP1, which is used to inhibit RNA alternative splicing events regulated by PTBP1. PTBP1-RNA-binding inhibitor P6 TFA exerts its effects by binding to the RNA recognition motif of PTBP1.